Halozyme Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: Increased 48% year-over-year to $481 million.

Royalty Revenue: Grew 50% year-over-year to $308 million.

Adjusted EBITDA: Rose 46% to $329 million, with a margin exceeding 65%.

Non-GAAP EPS: Increased to $2.28 from $1.54 in Q2 2025.

Net Income: Increased 39% to $229.9 million.

Cash Flow: Strong free cash flow generation, with $332.8 million in share repurchases in Q2.

2Strategic Updates and Business Highlights

ENHANZE Platform: Continued success with multiple products contributing to royalty revenues, including Opdivo SC, Ocrevus SC, and Rybrevant SC, which saw 80% growth quarter-on-quarter.

New Partnerships: Signed four new collaboration agreements in Q2, with a fifth in July, marking the highest pace of new deals in Halozyme's history. Notable partners include GSK and Incyte.

Development Pipeline: Progressing towards 13 ENHANZE development programs by the end of 2026, with two new Phase I studies initiated in Q2.

Hypercon Platform: Advancements in Hypercon are expected to mirror ENHANZE's success, with clinical supply preparations underway for 2027.

3Forward Guidance and Outlook

2026 Revenue Guidance: Raised to $1.835 billion - $1.91 billion, reflecting year-over-year growth of 31% to 37%.

Royalty Revenue Guidance: Increased to $1.22 billion - $1.245 billion, indicating growth of 41% to 43%.

Adjusted EBITDA Guidance: Expected between $1.225 billion and $1.28 billion, including planned investments in Hypercon and SurfBio.

4Bad News, Challenges, or Points of Concern

Merck Litigation: Ongoing legal disputes with Merck regarding patent infringements, with active injunctions pursued in multiple countries. Uncertainty remains regarding U.S. litigation timelines.

Competitive Pressures: Concerns about competitors like Alteogen, which may be working with targets that Halozyme has licensed exclusively. However, Halozyme maintains a competitive edge due to its established track record and expertise.

Investment in Hypercon: While Hypercon presents growth opportunities, the exact investment required and its impact on margins remain unclear.

5Notable Q&A Insights

Royalty Growth Drivers: Analysts inquired about the expected acceleration in royalty revenue for the second half of 2026, which is anticipated to be driven by new product launches and existing product performance.

Target Exclusivity: Discussions around exclusivity agreements suggest a mix of exclusive and non-exclusive licenses, allowing for broader collaboration opportunities.

Hypercon Pipeline: Future launches from Hypercon are expected to contribute significantly to revenue, with projections of five to seven launches by the mid-2030s.

M&A Strategy: The company remains focused on organic growth for 2026, with M&A opportunities considered only if they align with strategic goals. Overall, Halozyme reported a strong quarter with significant growth in revenue and partnerships, while maintaining a positive outlook for the future despite ongoing legal challenges and competitive pressures.